Tenaya Therapeutics, Inc. – NASDAQ:TNYA

Add to watchlist

$1.15

-0.35

-23.33%

Market closed

Open in 2 days

-57.27%

month

-57.27%

quarter

-55.62%

year

Market Cap	132.29M
Enterprise value	55.19M

P/E	-1.11
EV/Sales	N/A
EV/EBITDA	69.03
Price/Sales	N/A
Price/Book	0.55
PEG ratio	0.27
EPS	-1.68

Revenue	N/A
EBITDA	-120.14M
Income	-124.57M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA): Profit margin
Jun 2023	0	-33.26M
Sep 2023	0	-29.14M
Dec 2023	17.66M	-29.93M	-169.47%
Mar 2024	0	-32.22M

Tenaya Therapeutics Financials Estimate

Q Y

Tenaya Therapeutics, Inc. (NASDAQ:TNYA): Analyst Estimates
Sep 2025	0	-38.94M
Oct 2025	0	-27.46M
Dec 2025	0	-30.04M
Mar 2026	0	-35.34M

Analysts Price target
Financials & Ratios estimates

Tenaya Therapeutics, Inc. (NASDAQ:TNYA): Earnings per share (EPS)
2023-11-08	-0.47	-0.39
2024-03-18	-0.45	-0.4
2024-05-14	-0.43	-0.4

Tenaya Therapeutics, Inc. (NASDAQ:TNYA): Debt to assets
Jun 2023	220754000	30.81M	13.96%
Sep 2023	193397000	28.51M	14.74%
Dec 2023	170515000	31.09M	18.23%
Mar 2024	184899000	26.71M	14.45%

Tenaya Therapeutics, Inc. (NASDAQ:TNYA): Cash Flow
Jun 2023	-26.22M	25.08M	4.17M
Sep 2023	-23.63M	30.48M	0
Dec 2023	-21.92M	-14.91M	371K
Mar 2024	-28.66M	-4.48M	46.77M

Tenaya Therapeutics alternative data

Tenaya Therapeutics
Employees

Tenaya Therapeutics, Inc. (NASDAQ:TNYA): Employee count
Aug 2023	141
Sep 2023	141
Oct 2023	141
Nov 2023	141
Dec 2023	141
Jan 2024	141
Feb 2024	141
Mar 2024	140
Apr 2024	140
May 2024	140
Jun 2024	140
Jul 2024	140

Tenaya Therapeutics
Hedge Funds Holdings Q1 2023

22.51% -77.49%

of TNYA is owned by hedge funds

34 -33

hedge funds hold TNYA stock

10.09M -37.03M

shares is hold by hedge funds

TNYA hedge funds holdings changes

Tenaya Therapeutics
Insider Trading

Tenaya Therapeutics, Inc. (NASDAQ:TNYA): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	4444444	29309
Mar 2024	0	3300
Aug 2024	0	19539
Nov 2024	0	2258

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	18 Nov 2024	SAITO CHIHIRO officer: SVP, Accounting and Fin. Ops. officer: SVP, Accounting and Fi..	Common Stock	2,258	$2.12	$4,787
Sale	16 Aug 2024	SAITO CHIHIRO officer: SVP, Accounting and Fin. Ops. officer: SVP, Accounting and Fi..	Common Stock	902	$2.9	$2,611
Sale	16 Aug 2024	SAITO CHIHIRO officer: SVP, Accounting and Fin. Ops. officer: SVP, Accounting and Fi..	Common Stock	654	$2.9	$1,893
Sale	16 Aug 2024	SAITO CHIHIRO officer: SVP, Accounting and Fin. Ops. officer: SVP, Accounting and Fi..	Common Stock	807	$2.9	$2,336
Sale	16 Aug 2024	TINGLEY WHITTEMORE officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	5,803	$2.9	$16,800
Sale	16 Aug 2024	TINGLEY WHITTEMORE officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	1,625	$2.9	$4,704
Sale	16 Aug 2024	ALI FARAZ director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	5,802	$2.9	$16,797
Sale	16 Aug 2024	ALI FARAZ director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	3,946	$2.9	$11,424
Sale	5 Mar 2024	HOEY TIMOTHY officer: Chief Sc..	Common Stock	3,300	$7	$23,100
Sale	20 Feb 2024	HOEY TIMOTHY officer: Chief Sc..	Common Stock	6,369	$5.31	$33,813

TNYA insider trading transactions

Tenaya Therapeutics
Executives

Insider	Age	Compensation
Mr. Faraz Ali M.B.A. (1973) Chief Executive Officer, Sec. & Director	52	$552,800
Dr. Timothy Hoey Ph.D. (1959) Chief Scientific Officer	66	$473,560
Mr. Whittemore G. Tingley M.D., PH.D. (1967) Chief Medical Officer	58	$467,520
Dr. Deepak Srivastava M.D. (1966) Scientific Founder, Chairman of Scientific Advisory Board & Director	59	$75,000

Tenaya Therapeutics
Latest News

Tuesday, 17 December 2024
14:03	Tenaya Therapeutics price target lowered to $6 from $8 at Leerink	https://thefly.com
Monday, 16 December 2024
16:30	Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024	globenewswire.com
Wednesday, 6 November 2024
16:05	Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Thursday, 17 October 2024
16:30	Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM	globenewswire.com
Tuesday, 3 September 2024
08:30	Tenaya Therapeutics to Participate in Upcoming Investment Conferences	globenewswire.com
Tuesday, 30 July 2024
08:49	5 Penny Stocks With 250% Upside in 1 Year According to Wall Street	247wallst.com
Thursday, 27 June 2024
17:00	Tenaya Therapeutics Announces Research Leadership Updates	globenewswire.com
Tuesday, 18 June 2024
16:30	Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit	globenewswire.com
Tuesday, 14 May 2024
16:05	Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Thursday, 2 May 2024
17:00	Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting	globenewswire.com
Monday, 18 March 2024
16:05	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	globenewswire.com
08:30	Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine	globenewswire.com
Tuesday, 27 February 2024
16:30	Tenaya Therapeutics to Participate in Upcoming March Investor Conferences	GlobeNewsWire
Monday, 26 February 2024
10:56	Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?	Zacks Investment Research
Sunday, 18 February 2024
11:20	Insider Buying: Taking a Controlling Stake in a Struggling Retailer?	24/7 Wall Street
Friday, 9 February 2024
10:56	Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet	Zacks Investment Research
Friday, 26 January 2024
13:01	Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why	Zacks Investment Research
Thursday, 21 September 2023
16:05	Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences	GlobeNewsWire
Thursday, 31 August 2023
16:05	Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference	GlobeNewsWire
Monday, 15 May 2023
11:26	Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade	Zacks Investment Research
Sunday, 23 April 2023
16:02	3 Penny Stocks to Buy for 100% Returns	InvestorPlace
Thursday, 20 April 2023
14:46	Why This Nasdaq Stock Caught Fire This Week	The Motley Fool
Tuesday, 7 February 2023
17:17	Tenaya Therapeutics to Participate in Upcoming Investor Conferences	GlobeNewsWire
Thursday, 26 January 2023
13:33	Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research
Friday, 20 January 2023
14:14	4 Penny Stocks To Buy In January According To Insiders	PennyStocks
Monday, 14 November 2022
13:33	5 Penny Stocks To Buy According To Analysts, Targets Up To 992%	PennyStocks
Tuesday, 4 October 2022
08:30	Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress	GlobeNewsWire
Friday, 20 May 2022
08:30	Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference	Business Wire
Thursday, 24 March 2022
08:30	Tenaya Therapeutics to Participate in Upcoming Investor Conferences	Business Wire
Tuesday, 8 February 2022
13:50	Why Earnings Season Could Be Great for Tenaya Therapeutics (TNYA)	Zacks Investment Research

Frequently Asked Questions (FAQ)

What's the price of Tenaya Therapeutics stock today?

One share of Tenaya Therapeutics stock can currently be purchased for approximately $1.15.
When is Tenaya Therapeutics's next earnings date?

Unfortunately, Tenaya Therapeutics's (TNYA) next earnings date is currently unknown.
Does Tenaya Therapeutics pay dividends?

No, Tenaya Therapeutics does not pay dividends.
How much money does Tenaya Therapeutics make?

Tenaya Therapeutics has a market capitalization of 132.29M. Tenaya Therapeutics made a loss 124.08M US dollars in net income (profit) last year or -$0.4 on an earnings per share basis.
What is Tenaya Therapeutics's stock symbol?

Tenaya Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TNYA".
What is Tenaya Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Tenaya Therapeutics?

Shares of Tenaya Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Tenaya Therapeutics's key executives?
Tenaya Therapeutics's management team includes the following people:
- Mr. Faraz Ali M.B.A. Chief Executive Officer, Sec. & Director(age: 52, pay: $552,800)
- Dr. Timothy Hoey Ph.D. Chief Scientific Officer(age: 66, pay: $473,560)
- Mr. Whittemore G. Tingley M.D., PH.D. Chief Medical Officer(age: 58, pay: $467,520)
- Dr. Deepak Srivastava M.D. Scientific Founder, Chairman of Scientific Advisory Board & Director(age: 59, pay: $75,000)
Is Tenaya Therapeutics founder-led company?

Yes, Tenaya Therapeutics is a company led by its founder Dr. Deepak Srivastava M.D..
How many employees does Tenaya Therapeutics have?

As Jul 2024, Tenaya Therapeutics employs 140 workers.
When Tenaya Therapeutics went public?

Tenaya Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 30 Jul 2021.
What is Tenaya Therapeutics's official website?

The official website for Tenaya Therapeutics is tenayatherapeutics.com.
Where are Tenaya Therapeutics's headquarters?

Tenaya Therapeutics is headquartered at 171 Oyster Point Boulevard, South San Francisco, CA.
How can i contact Tenaya Therapeutics?

Tenaya Therapeutics's mailing address is 171 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 08256900.

Tenaya Therapeutics, Inc.

tenayatherapeutics.com

Exchange:

NASDAQ

Full time employees:

140

Industry:

Biotechnology

Sector:

Healthcare

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

+65 08256900

171 Oyster Point Boulevard
South San Francisco, CA 94080

CIK: 0001858848
ISIN: US87990A1060
CUSIP: 87990A106